Editorial on “Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension”

Lindsay M. Forbes

https://doi.org/10.1002/pul2.12444

Abstract

Recommended therapies for pulmonary arterial hypertension (PAH) have until recently targeted pathways with predominant effects of pulmonary vasodilation.1 The recent addition to treatment options of sotatercept, an activin signaling inhibitor which rebalances pro- and antiproliferative signaling, bolsters a longstanding goal of targeting pathogenic pulmonary vascular remodeling.1, 2 Additional remodeling targets exist within the “cancer paradigm” of PAH pathogenesis, i.e. within a variety of proliferative and apoptotic pathways active in pulmonary arterial smooth muscle and endothelial cells.3 A potential role for targeting pathways shared with cancer biology is of great interest.

Read the full editorial